Efficacy of tolperisone versus meloxicam in the treatment of nonspecific acute neck pain
https://doi.org/10.14412/2074-2711-2020-2-37-41
Abstract
Neck pain is a widespread disease that significantly impairs quality of life in patients. General approaches to managing patients with acute neck pain are generally consistent with the recommendations for the treatment of acute back pain: its pharmacotherapy includes nonsteroidal antiinflammatory drugs (NSAIDs) and muscle relaxants.
Objective of the observational program: to compare the efficiency of treatment for nonspecific acute neck pain with tolperisone 150 mg/day, followed by dose escalation up to 450 mg/day, versus meloxicam 15 mg/day for 14 days.
Patients and methods. The observational program covered 37 patients aged 18–65 years who were diagnosed with acute nonspecific neck pain; of them 19 patients made up Group 1 and 18 formed Group 2. Group 1 was prescribed tolperisone (Calmirex) as tablets: 150 mg/day on day 1, 300 mg/day on day 2, and 450 mg/day on day 3 until the end of therapy. On day 1 of the investigation, Group 2 received meloxicam 15 mg/day in two divided doses (7.5 mg in the morning and evening). At baseline and on days 7 and 14 days of therapy, the investigators assessed the dynamics of pain using a visual analogue scale (VAS), as well as its intensity at rest and during movement; neck disability index (NDI) and recorded adverse events.
Results and discussion. The two groups showed a significant decrease in pain intensity on both 7 and 14 days of therapy. The rate of effect onset was significantly faster in the meloxicam group. On day 14 of treatment, both patient groups showed a considerably better functional state in terms of activity limitations due to neck pain (NDI); patients' perceptions of therapy were rated as good and excellent in most cases. On 14 days of therapy, the degree of pain reduction in the meloxicam group was higher, but the differences with that in the tolperisone group did not reach statistical significance, which can indicate the comparable efficacy of the drugs.
Conclusion. The data of this observational program are consistent with the recommendations for the treatment of nonspecific acute neck pain, which indicate NSAIDs and muscle relaxants as drugs for the treatment of this disease.
About the Authors
K. V. Skorobogatykh
OOO «University Clinic of Headache»
Russian Federation
2, Molodogvardeiskaya St., Build. 1, Moscow 121351, Russia
Russian Federation
2, Molodogvardeiskaya St., Build. 1, Moscow 121351, Russia
Yu. E. Azimova
OOO «University Clinic of Headache»
Russian Federation
2, Molodogvardeiskaya St., Build. 1, Moscow 121351, Russia
Russian Federation
2, Molodogvardeiskaya St., Build. 1, Moscow 121351, Russia
References
1. Cote P, Cassidy DJ, Carroll LJ, Kristman V. The annual incidence and course of neck pain in the general population: a population-based cohort study. Pain. 2004 Dec;112(3):267-73.
2. Cote P, Cassidy JD, Carroll L. The Saskatchewan Health and Back Pain Survey. Spine (Phila Pa 1976). 1998 Aug 1;23(15):1689-98.
3. Urwin M, Symmons D, Allison T, et al. Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. Ann Rheum Dis. 1998 Nov;57(11):649-55.
4. Hill J, Lewis M, Papageorgiou AC, et al. Predicting Persistent Neck Pain. Spine (Phila Pa 1976). 2004 Aug 1;29(15):1648-54.
5. Bovim G, Schrader H, Sand T. Neck Pain in the General Population. Spine (Phila Pa 1976). 1994 Jun 15;19(12):1307-9. doi:10.1097/00007632-199406000-00001
6. Hackett GI, Hudson MF, Wylie JB, et al. Evaluation of the efficacy and acceptability to patients of a physiotherapist working in a health centre. Br Med J (Clin Res Ed). 1987 Jan 3; 294(6563):24-6.
7. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6.
8. Binder A. The diagnosis and treatment of nonspecific neck pain and whiplash. Eura Medicophys. 2007 Mar;43(1):79-89.
9. Kä äriä S, Laaksonen M, Rahkonen O, et al. Risk factors of chronic neck pain: a prospective study among middle-aged employees. Eur J Pain. 2012 Jul;16(6):911-20. doi: 10.1002/j.1532-2149.2011.00065.x. Epub 2011 Dec 19.
10. Nilsen TI, Holtermann A, Mork PJ. Physical exercise, body mass index, and risk of chronic pain in the low back and neck/shoulders: longitudinal data from the Nord- Trondelag Health Study. Am J Epidemiol. 2011 Aug 1;174(3): 267-73. doi: 10.1093/aje/kwr087. Epub 2011 Jun 1.
11. Guzman J, Hurwitz EL, Carroll LJ, et al. Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. Spine (Phila Pa 1976). 2008 Feb 15;33(4 Suppl): S14-23. doi: 10.1097/BRS.0b013e3181643efb.
12. https://cks.nice.org.uk/neck-pain-nonspecific
13. Coskun O, Ucler S, Karakurum B, et al. Magnetic resonance imaging of patients with cervicogenic headache. Cephalalgia. 2003 Oct; 23(8):842-5.
14. Parfenov VA, Yakhno NN, Kukushkin ML, et al. Acute nonspecific (musculoskeletal) low back pain Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):4-11. (In Russ.). doi: 10.14412/2074-2711-2018-2-4-11
15. Brune, K, Patrignani P. New insights into the use of currently available non-steroidal antiinflammatory drugs. J Pain Res. 2015 Feb 20;8: 105-18. doi: 10.2147/JPR.S75160.eCollection 2015.
16. Van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for non-specific low-back pain. Cochrane Database Syst Rev. 2003;(2): CD004252.
17. Hofer D, Lohberger B, Steinecker B, et al. A comparative study of the action of tolperisone on seven different voltage dependent sodium channel isoforms. Eur J Pharmacol. 2006 May 24;538(1-3):5-14. Epub 2006 Mar 21. doi: 10.1016/j.ejphar.2006.03.034
18. Kocsis P, Farkas S, Fodor L, et al. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec; 315(3):1237-46. Epub 2005 Aug 26. doi: 10.1124/jpet.105.089805
19. Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated doses of tolperisone hydrochloride in treatment of painful muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain. 1996 Oct;67 (2-3):417-25.
20. Rao R, Panghate A, Chandanwale A, et al. Clinical Comparative Study: Efficacy and Tolerability of Tolperisone and Thiocolchicoside in Acute Low Back Pain and Spinal Muscle Spasticity. Asian Spine J. 2012 Jun;6(2):115-22. doi: 10.4184/asj.2012.6.2.115. Epub 2012 May 31.
21. Vernon H, Mior S. The Neck Disability Index: A study of reliability and validity. J Manipulative Physiol Ther. 1991 Sep; 14(7):409-15.
22. Kukushkin ML, Brylev LV, Laskov VB, et al. The results of a randomized double-blind parallel study of efficacy and safety of the use tolperisone in patients with acute nonspecific pain in the lower back. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(11): 69-78. (In Russ.).
Review
Supporting agencies: This article has been supported by Sotex PharmFirma.
For citations:
Skorobogatykh K.V., Azimova Yu.E. Efficacy of tolperisone versus meloxicam in the treatment of nonspecific acute neck pain. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(2):37-41. (In Russ.) https://doi.org/10.14412/2074-2711-2020-2-37-41
Views: 9902
Email this article 